Abstract

The utilization of robot-assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer is increasing, despite limited data comparing RAMIE with other surgical approaches. To evaluate the literature for clinical outcomes of RAMIE compared with video-assisted minimally invasive esophagectomy (VAMIE) and open esophagectomy (OE). A systematic search of PubMed, Cochrane, Ovid Medline, and Embase databases from January 1, 2013, to May 6, 2020, was performed. Studies that compared RAMIE with VAMIE and/or OE for cancer were included. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline, data were extracted by independent reviewers. A random-effects meta-analysis of 9 propensity-matched studies was performed for the RAMIE vs VAMIE comparison only. A narrative synthesis of RAMIE vs VAMIE and OE was performed. The outcomes of interest were intraoperative outcomes (ie, estimated blood loss [EBL], operative time, lymph node [LN] harvest), short-term outcomes (anastomotic leak, recurrent laryngeal nerve [RLN] palsy, pulmonary and total complications, and 90-day mortality), and long-term oncologic outcomes. Overall, 21 studies (2 randomized clinical trials, 11 propensity-matched studies, and 8 unmatched studies) with 9355 patients were included. A meta-analysis was performed with 9 propensity-matched studies comparing RAMIE with VAMIE. The random-effects pooled estimate found an adjusted risk difference (RD) of -0.06 (95% CI, -0.11 to -0.01) favoring fewer pulmonary complications with RAMIE. There was no evidence of differences between RAMIE and VAMIE in LN harvest (mean difference [MD], -1.1 LN; 95% CI, -2.45 to 0.25 LNs), anastomotic leak (RD, 0.0; 95% CI, -0.03 to 0.03), EBL (MD, -6.25 mL; 95% CI, -18.26 to 5.77 mL), RLN palsy (RD, 0.01; 95% CI, -0.08 to 0.10), total complications (RD, 0.05; 95% CI, -0.01 to 0.11), or 90-day mortality (RD, -0.01; 95% CI, -0.02 to 0.0). There was low certainty of evidence that RAMIE was associated with a longer disease-free survival compared with VAMIE. For OE comparisons (data not pooled), RAMIE was associated with a longer operative time, decreased EBL, and less pulmonary and total complications. In this study, RAMIE had similar outcomes as VAMIE but was associated with fewer pulmonary complications compared with VAMIE and OE. Studies on long-term functional and cancer outcomes are needed.

Highlights

  • Worldwide adoption of robot-assisted surgery continues to increase, for cancer and thoracic operations.[1,2,3] Esophageal cancer is the seventh most common cancer diagnosis in the world each year, with an estimated 604 000 new cases in 2020.4 Esophagectomy is an important component of esophageal cancer treatment, often combined with perioperative chemoradiation for advanced disease

  • There was no evidence of differences between Robot-assisted minimally invasive esophagectomy (RAMIE) and video-assisted minimally invasive esophagectomy (VAMIE) in lymph nodes (LN) harvest, anastomotic leak (RD, 0.0; 95% CI, −0.03 to 0.03), estimated blood loss (EBL) (MD, −6.25 mL; 95% CI, −18.26 to 5.77 mL), recurrent laryngeal nerve (RLN) palsy (RD, 0.01; 95% CI, −0.08 to 0.10), total complications (RD, 0.05; 95% CI, −0.01 to 0.11), or 90-day mortality (RD, −0.01; 95% CI, −0.02 to 0.0)

  • There was low certainty of evidence that RAMIE was associated with a longer disease-free survival compared with VAMIE

Read more

Summary

Introduction

Worldwide adoption of robot-assisted surgery continues to increase, for cancer and thoracic operations.[1,2,3] Esophageal cancer is the seventh most common cancer diagnosis in the world each year, with an estimated 604 000 new cases in 2020.4 Esophagectomy is an important component of esophageal cancer treatment, often combined with perioperative chemoradiation for advanced disease. It is performed using a variety of approaches, including open, conventional minimally invasive (thoracoscopic and laparoscopic), or robot-assisted techniques.

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call